Results 11 to 20 of about 14,396 (215)

Reducing inequities in access to postpartum hemorrhage prevention: Reframing advance distribution of misoprostol as a test case for health system responsiveness and adaptation. [PDF]

Int J Gynaecol Obstet
Abstract Advance distribution of misoprostol is an evidence‐based strategy for preventing postpartum hemorrhage (PPH) at births without skilled health personnel present. Despite its lifesaving potential, initial momentum behind this intervention has slowed over the last decade and has not been renewed since WHO released updated guidelines in 2020 or ...
Tappis H, Doi N, Bhola C, Bamba Y, Lathrop E.   +4 more
europepmc   +2 more sources

Igniting the spark in six countries to transform the trajectory of postpartum hemorrhage across the globe: An overview of the AMPLI-PPHI project. [PDF]

Int J Gynaecol Obstet
Abstract Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide, disproportionately affecting women in low‐ and middle‐income countries. Despite updated WHO recommendations and the availability of newer technologies—including heat‐stable carbetocin, tranexamic acid as part of a clinical care bundle, misoprostol, and ...
Roman E.
europepmc   +2 more sources

Hyperpyrexia After Rectal Misoprostol Administration-A Rare Side Effect of Misoprostol: Case Report

Novelty in Biomedicine, 2022
Background: Misoprostol is a safe drug that is one of the prostaglandins analogs. It has uterotonic solid potential and is good for postpartum hemorrhage (PPH).
Masoumeh Mirzamoradi, Yekta Parsa
doaj   +2 more sources

The role of exchange hubs and learning between countries and regions in strengthening the implementation and expansion of essential products for postpartum hemorrhage. [PDF]

Int J Gynaecol Obstet
Abstract Postpartum hemorrhage (PPH) affects about 6%–10% of women giving birth and is the leading cause of maternal mortality worldwide. Following its launch in the Democratic Republic of the Congo, Guinea, India, and Kenya in October 2022, and more recently in Nigeria and Zambia, the Unitaid‐supported Accelerating Measurable Progress and Leveraging ...
Sy T, Diallo A, Traore Y, Kourouma D, Traore O, Bolamba VL, Irinyenikan TA, Gooden R, Racine S.   +8 more
europepmc   +2 more sources

Moving beyond a legacy paradigm: A vision for equitable access to quality medicines in Africa. [PDF]

Int J Gynaecol Obstet
Abstract Ensuring the availability of quality medicines is fundamental to achieving health outcomes and safeguarding public health. However, in many low‐ and middle‐income countries, especially across Africa, the current quality assurance paradigm—largely driven by historical donor preferences for WHO prequalification and stringent regulatory authority
Doi N, Orji BC, Ruffo M, Mukumbayi P, Kibonge S, Muthamia MM, Tappis H, Biayi F, Kassim TY, Ndwiga A.   +9 more
europepmc   +2 more sources

Misoprostol versus Letrozol with Misoprostol in Management of First Trimesteric Missed Miscarriage [PDF]

Al-Azhar International Medical Journal, 2021
Background and objective: The objective of this work is to match the security and effectiveness of two treatment modalities (Misoprostol versus Letrozol with Misoprostol) in medical treatment of 1st trimesteric missed miscarriages.
Mofeed Mohammed, Farid Hassan, Abd Elazeem Afifi   +2 more
doaj   +1 more source

Evaluation of Low-dose and High-dose Intravaginal Misoprostol for Induction of Labour: A Randomised, Double-blinded, Single Centre Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Misoprostol is a synthetic prostaglandin E1 analogue widely used for cervical ripening and labour induction. However, optimal dose of misoprostol required to induce labour is still controversial.
Gowthami Mummalaneni, Thodeti Chaitanya Sravanthi, I Sridhar, Suresh Babu Sayana, Meela Ranjith Kumar   +4 more
doaj   +1 more source

Potency and acceptability of oral misoprostol compared with vaginal misoprostol prior to first trimester abortion [PDF]

New Indian Journal of OBGYN, 2020
Objectives: Present study was done to assess the effectiveness and acceptability of oral misoprostol compared with vaginal misoprostol for cervical priming before termination of first trimester pregnancy.
Varsha Kotwal
doaj   +1 more source

The difference of Bishop score change and labor event between oral and vaginal misoprostol in pregnancy beyond 41 weeks

Majalah Obstetri dan Ginekologi, 2023
HIGHLIGHTS • Oral misoprostol is more effective than vaginal misoprostol in cervical ripening as a part of induction of labor. • Oral misoprostol is as safe as vaginal misoprostol.   ABSTRACT Objective: To compare Bishop score changes and labor
Maskasoni Maskasoni, Julian Dewantiningrum   +1 more
doaj   +1 more source

Comparative Study of Oral and Vaginal Misoprostol for Induction of Labour, Maternal and Foetal Outcome [PDF]

Journal of Clinical and Diagnostic Research, 2013
Background: Misoprostol is a new promising agent for cervical ripening and induction of labour .The ideal dose, route and frequency of administration of misoprostol are still under investigation.
Kambhampati Komala, Meherlatha Reddy, Iqbal Jehan Quadri, Suneetha B., Ramya V.   +4 more
doaj   +1 more source